Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B
Phase 2
Terminated
- Conditions
- Chronic Hepatitis B
- Registration Number
- NCT00040144
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Brief Summary
The purpose of this study was to determine the safety and antiviral hepatitis B virus (HBV) activity of ACH126, 433 in the treatment of adults with lamivudine-resistant chronic hepatitis B.
- Detailed Description
Evaluation of the safety and antiviral activity of 3 dose levels of ACH126, 433 over a 12-week treatment in the population is described.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 85
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of ACH126,433 (b-L-Fd4C) demonstrate antiviral activity against lamivudine-resistant HBV strains?
How does ACH126,433 compare to other nucleoside analogs in treating lamivudine-resistant chronic hepatitis B?
Which biomarkers correlate with virological response to ACH126,433 in lamivudine-resistant HBV patients?
What adverse events were observed in NCT00040144 and how were they managed in lamivudine-resistant HBV treatment?
Are there combination therapies involving ACH126,433 that improve outcomes for lamivudine-resistant chronic hepatitis B?
Trial Locations
- Locations (1)
Clinical Trial Site
🇨🇳Hong Kong, China
Clinical Trial Site🇨🇳Hong Kong, China